Skin in The Game: The Cost Consequences of Skin Cancer Diagnosis, Treatment and Care in Northern Ireland

Author:

McFerran Ethna,Donaldson Sarah,Lawler Mark

Abstract

AbstractBackgroundSkin cancer is a prevalent type of cancer in the UK. Its rising incidence and mortality rates are expected to result in substantial financial implications, particularly on diagnostic and treatment services for skin cancer management in Northern Ireland. Such anticipated disease increases underscore the need for prevention and control measures that should guide policymaking and planning efforts.MethodsWe conducted a retrospective cost study to measure the burden of skin cancer in Northern Ireland from a healthcare system perspective. Our data-driven model utilized bottom-up methodology1,2and reported 2018 costs using NHS reference unit costs (UK£) for skin cancer diagnosis and treatment patient pathways. Sensitivity analyses were performed, including varying diagnostic volumes by applying multipliers for benign cases and assuming a diagnostic conversion rate of 6.8%. An alternative chemotherapy regimen compliance rate was also examined at 75% as compared to base case. Proportional increases were projected based on future estimated increases of 9% and 28% in melanoma cases for diagnostic, treatment, and follow-up volumes specifically related to malignant melanoma.ResultsAs of 2018, NICR recorded 4142 non-melanoma skin cancers (NMSC) and 423 malignant melanoma (MM) cases, averaging 17.5 new patients per trust weekly. The total costs for managing NMSC was £1,815,936, whereas that for MM skin cancer costs was £12,364,220, out of which £8,792,208 accounted for procurement, administration, and chemotherapy drug use. Healthcare providers spent a total of £17,024,115 on skin cancer care. Sensitivity analysis suggest diagnostic cost would either reduce by £781k to £3,061,524 or increase significantly to £11,212,183 based on referral volume assumptions. If base case rates rise by 9 or 28% estimated total costs of treating skin cancer will increase to £18.1 million and £20.4 million respectively.ConclusionsSkin cancer management costs in Northern Ireland vary from ∼£14.3m to £26.2m depending on diagnostic referral assumptions. Malignant melanoma costs have risen ∼10 fold over the past decade mainly due to chemotherapy costs. Predicted 28% increase in melanoma cases by 2040 would lead to £3.3m of additional referral, diagnostic and treatment expenditures, which with inflation adjustment to a further budget requirement of approximately £6.4 million by 2022 rates.

Publisher

Cold Spring Harbor Laboratory

Reference39 articles.

1. Cost-of-illness studies: concepts, scopes, and methods;Clin. Mol. Hepatol,2014

2. Measuring current and future cost of skin cancer in England;J. Public Heal. (United Kingdom),2014

3. Public Health England. Factors influencing survival from melanoma in England, Northern Ireland and Scotland. National Cancer Intelligence Network Factors influencing survival from melanoma in England, Northern Ireland and Scotland (2015).

4. Cancer Research UK. Melanoma skin cancer statistics. 1–7 (2023). Available at: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/melanoma-skin-cancer. (Accessed: 11th January 2023)

5. Global Coalition for Melanoma Patient Advocacy & Euro Melanoma. 2020 Melanoma Skin Cancer Report-Stemming the Global Epidemic. 16 (2020).

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3